人乳头瘤病毒9价疫苗对手术后病毒清除的影响：一项单中心回顾性观察研究

IF 2.1 4区医学 Q2 OBSTETRICS & GYNECOLOGY

European journal of obstetrics, gynecology, and reproductive biology Pub Date : 2025-04-20 DOI:10.1016/j.ejogrb.2025.113994

Mario Palumbo , Giada Lavitola , Claudia Di Filippo , Virginia Foreste , Maddalena Granata , Oriana Imperatore , Mario Ascione , Luigi Della Corte , Giuseppe Bifulco

{"title":"人乳头瘤病毒9价疫苗对手术后病毒清除的影响：一项单中心回顾性观察研究","authors":"Mario Palumbo , Giada Lavitola , Claudia Di Filippo , Virginia Foreste , Maddalena Granata , Oriana Imperatore , Mario Ascione , Luigi Della Corte , Giuseppe Bifulco","doi":"10.1016/j.ejogrb.2025.113994","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>The effectiveness of post-treatment HPV vaccination with the Human papillomavirus 9-valent <strong>(</strong>9vHPV) vaccine in women treated with loop electrosurgical excision procedure (LEEP) for high-grade cervical intraepithelial neoplasia (CIN2-3) or laser ablation (LA) for low-grade lesions (CIN1) remains a topic of ongoing research.</div><div><em>Study design:</em> This single-center retrospective observational study included 326 women aged 25 to 65 years who underwent surgical treatment between 2020 and 2024. Participants were divided into two groups: vaccinated (V) and non-vaccinated (NV). A further stratification was then reported by age < 40 years (n = 174) and ≥ 40 years (n = 152).</div><div>The primary outcomes were HPV test results and colposcopy findings 6–15 months post-treatment, evaluating the potential adjuvant effect of HPV vaccination.</div></div><div><h3>Results</h3><div>The vaccinated group (V-group) comprised 68 % (222/326) of participants, while 32 % (104/326) were unvaccinated (NV-group). Among women treated for CIN1, a positive HPV test was detected in 38 % of unvaccinated women compared to 18 % in vaccinated women (p = 0.0169). Among those treated for CIN2-3, 18 % of unvaccinated women had a positive HPV test, compared to 8 % in the vaccinated group (p = 0.0353). Vaccination, also in women with an age ≥ 40-year-old had a statistically significant effect in reducing the proportion of women with a positive HPV test (p = 0.0100).</div></div><div><h3>Conclusion</h3><div>Human papillomavirus 9-valent vaccine was associated with a significant reduction in the proportion of women with a positive HPV test. These findings support its potential role in tertiary prevention of HPV-related cervical disease, particularly in reducing HPV persistence after surgical treatment.</div></div>","PeriodicalId":11975,"journal":{"name":"European journal of obstetrics, gynecology, and reproductive biology","volume":"310 ","pages":"Article 113994"},"PeriodicalIF":2.1000,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of Human papillomavirus 9-valent vaccine on viral clearance after surgical treatment: A single-center retrospective observational study\",\"authors\":\"Mario Palumbo , Giada Lavitola , Claudia Di Filippo , Virginia Foreste , Maddalena Granata , Oriana Imperatore , Mario Ascione , Luigi Della Corte , Giuseppe Bifulco\",\"doi\":\"10.1016/j.ejogrb.2025.113994\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>The effectiveness of post-treatment HPV vaccination with the Human papillomavirus 9-valent <strong>(</strong>9vHPV) vaccine in women treated with loop electrosurgical excision procedure (LEEP) for high-grade cervical intraepithelial neoplasia (CIN2-3) or laser ablation (LA) for low-grade lesions (CIN1) remains a topic of ongoing research.</div><div><em>Study design:</em> This single-center retrospective observational study included 326 women aged 25 to 65 years who underwent surgical treatment between 2020 and 2024. Participants were divided into two groups: vaccinated (V) and non-vaccinated (NV). A further stratification was then reported by age < 40 years (n = 174) and ≥ 40 years (n = 152).</div><div>The primary outcomes were HPV test results and colposcopy findings 6–15 months post-treatment, evaluating the potential adjuvant effect of HPV vaccination.</div></div><div><h3>Results</h3><div>The vaccinated group (V-group) comprised 68 % (222/326) of participants, while 32 % (104/326) were unvaccinated (NV-group). Among women treated for CIN1, a positive HPV test was detected in 38 % of unvaccinated women compared to 18 % in vaccinated women (p = 0.0169). Among those treated for CIN2-3, 18 % of unvaccinated women had a positive HPV test, compared to 8 % in the vaccinated group (p = 0.0353). Vaccination, also in women with an age ≥ 40-year-old had a statistically significant effect in reducing the proportion of women with a positive HPV test (p = 0.0100).</div></div><div><h3>Conclusion</h3><div>Human papillomavirus 9-valent vaccine was associated with a significant reduction in the proportion of women with a positive HPV test. These findings support its potential role in tertiary prevention of HPV-related cervical disease, particularly in reducing HPV persistence after surgical treatment.</div></div>\",\"PeriodicalId\":11975,\"journal\":{\"name\":\"European journal of obstetrics, gynecology, and reproductive biology\",\"volume\":\"310 \",\"pages\":\"Article 113994\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-04-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European journal of obstetrics, gynecology, and reproductive biology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0301211525002635\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of obstetrics, gynecology, and reproductive biology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0301211525002635","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在接受环形电切手术（LEEP）治疗高级别宫颈上皮内瘤变（CIN2-3）或激光消融（LA）治疗低级别病变（CIN1）的妇女中，治疗后接种人乳头瘤病毒9价（9vHPV）疫苗的有效性仍是一个正在进行的研究课题。研究设计：这项单中心回顾性观察性研究包括326名年龄在25至65岁之间的女性，她们在2020年至2024年期间接受了手术治疗。参与者被分为两组：接种疫苗(V)和未接种疫苗（NV）。然后根据年龄报告了进一步的分层；40岁（n = 174）和≥40岁（n = 152）。主要结果是HPV检测结果和治疗后6-15个月的阴道镜检查结果，评估HPV疫苗接种的潜在辅助作用。结果接种组（v组）占68%(222/326)，未接种组（nv组）占32%（104/326）。在接受CIN1治疗的女性中，未接种疫苗的女性中HPV检测阳性的比例为38%，而接种疫苗的女性为18% （p = 0.0169）。在接受CIN2-3治疗的妇女中，18%未接种疫苗的妇女HPV检测呈阳性，而接种疫苗组为8% （p = 0.0353）。在年龄≥40岁的女性中接种疫苗对降低HPV检测阳性的女性比例有统计学意义（p = 0.0100）。结论人乳头瘤病毒9价疫苗与HPV检测阳性的女性比例显著降低相关。这些发现支持其在HPV相关宫颈疾病三级预防中的潜在作用，特别是在降低手术治疗后HPV持续性方面。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Impact of Human papillomavirus 9-valent vaccine on viral clearance after surgical treatment: A single-center retrospective observational study

Introduction

The effectiveness of post-treatment HPV vaccination with the Human papillomavirus 9-valent (9vHPV) vaccine in women treated with loop electrosurgical excision procedure (LEEP) for high-grade cervical intraepithelial neoplasia (CIN2-3) or laser ablation (LA) for low-grade lesions (CIN1) remains a topic of ongoing research.

Study design: This single-center retrospective observational study included 326 women aged 25 to 65 years who underwent surgical treatment between 2020 and 2024. Participants were divided into two groups: vaccinated (V) and non-vaccinated (NV). A further stratification was then reported by age < 40 years (n = 174) and ≥ 40 years (n = 152).

The primary outcomes were HPV test results and colposcopy findings 6–15 months post-treatment, evaluating the potential adjuvant effect of HPV vaccination.

Results

The vaccinated group (V-group) comprised 68 % (222/326) of participants, while 32 % (104/326) were unvaccinated (NV-group). Among women treated for CIN1, a positive HPV test was detected in 38 % of unvaccinated women compared to 18 % in vaccinated women (p = 0.0169). Among those treated for CIN2-3, 18 % of unvaccinated women had a positive HPV test, compared to 8 % in the vaccinated group (p = 0.0353). Vaccination, also in women with an age ≥ 40-year-old had a statistically significant effect in reducing the proportion of women with a positive HPV test (p = 0.0100).

Conclusion

Human papillomavirus 9-valent vaccine was associated with a significant reduction in the proportion of women with a positive HPV test. These findings support its potential role in tertiary prevention of HPV-related cervical disease, particularly in reducing HPV persistence after surgical treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European journal of obstetrics, gynecology, and reproductive biology 医学-妇产科学

CiteScore

4.60

自引率

3.80%

发文量

898

审稿时长

8.3 weeks

期刊介绍： The European Journal of Obstetrics & Gynecology and Reproductive Biology is the leading general clinical journal covering the continent. It publishes peer reviewed original research articles, as well as a wide range of news, book reviews, biographical, historical and educational articles and a lively correspondence section. Fields covered include obstetrics, prenatal diagnosis, maternal-fetal medicine, perinatology, general gynecology, gynecologic oncology, uro-gynecology, reproductive medicine, infertility, reproductive endocrinology, sexual medicine and reproductive ethics. The European Journal of Obstetrics & Gynecology and Reproductive Biology provides a forum for scientific and clinical professional communication in obstetrics and gynecology throughout Europe and the world.